StockData
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc. (VYGR) stock

VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3053% below fair value
$1.67+0.15 (+9.87%)

Close on Nov 18, 2026Market cap $102.90MP/E –Yield –

Voyager Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Voyager Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$121.42M. For fiscal 2025 it was -$135.06M. The highest annual figure on record is $74.66M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$135.06M–
FY2024Dec 31, 2024-$18.83M-125.2%
FY2023Dec 31, 2023$74.66M–
FY2022Dec 31, 2022-$15.00M–
FY2021Dec 31, 2021-$55.13M–
FY2020Dec 31, 2020-$108.81M-365.7%
FY2019Dec 31, 2019$40.95M–
FY2018Dec 31, 2018-$20.19M–
FY2017Dec 31, 2017-$65.34M–
FY2016Dec 31, 2016-$47.51M-218.0%
FY2015Dec 31, 2015$40.27M–
FY2014Dec 31, 2014-$14.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$25.84M–
Q1 FY2026Mar 31, 2026-$33.43M–
Q4 FY2025Dec 31, 2025-$30.89M–
Q3 FY2025Sep 30, 2025-$31.26M–
Q2 FY2025Jun 30, 2025-$34.37M–
Q1 FY2025Mar 31, 2025-$38.55M-168.1%
Q4 FY2024Dec 31, 2024-$14.68M–
Q3 FY2024Sep 30, 2024-$28.23M–
Q2 FY2024Jun 30, 2024-$32.55M–
Q1 FY2024Mar 31, 2024$56.63M-54.0%
Q4 FY2023Dec 31, 2023-$24.52M–
Q3 FY2023Sep 30, 2023-$21.83M–
Q2 FY2023Jun 30, 2023-$2.05M–
Q1 FY2023Mar 31, 2023$123.06M+257.8%
Q4 FY2022Dec 31, 2022-$13.18M-221.5%
Q3 FY2022Sep 30, 2022-$16.48M–
Q2 FY2022Jun 30, 2022-$19.73M–
Q1 FY2022Mar 31, 2022$34.39M–
Q4 FY2021Dec 31, 2021$10.85M–
Q3 FY2021Sep 30, 2021-$21.37M–
Q2 FY2021Jun 30, 2021-$22.94M–
Q1 FY2021Mar 31, 2021-$21.67M–
Q4 FY2020Dec 31, 2020-$25.53M–
Q3 FY2020Sep 30, 2020-$29.89M–
Q2 FY2020Jun 30, 2020-$23.08M–
Q1 FY2020Mar 31, 2020-$30.31M-124.4%
Q4 FY2019Dec 31, 2019-$26.74M–
Q3 FY2019Sep 30, 2019-$22.75M–
Q2 FY2019Jun 30, 2019-$33.62M–
Q1 FY2019Mar 31, 2019$124.06M+163.9%
Q4 FY2018Dec 31, 2018-$24.87M–
Q3 FY2018Sep 30, 2018-$18.50M–
Q2 FY2018Jun 30, 2018-$23.83M–
Q1 FY2018Mar 31, 2018$47.00M–
Q4 FY2017Dec 31, 2017-$15.00M–
Q3 FY2017Sep 30, 2017-$16.30M–
Q2 FY2017Jun 30, 2017-$16.80M–
Q1 FY2017Mar 31, 2017-$17.24M–
Q4 FY2016Dec 31, 2016-$16.96M–
Q3 FY2016Sep 30, 2016-$10.69M–

More Voyager Therapeutics figures

See a number that looks wrong?